Boston Scientific completes acquisition of NxThera — 3 insights

Boston Scientific officially acquired NxThera, the company behind the Rezum system.

Here's what you should know.

1. The Rezum system is a minimally invasive therapy for patients with symptomatic benign prostatic hyperplasia.

2. Boston Scientific is incorporating NxThera into its urology and pelvic health business.

3. Boston Scientific acquired NxThera because the company feels the Rezum system compliments its existing offerings for symptomatic BPH.

Boston Scientific Executive Vice President and MedSurg President Dave Pierce said, "We are confident in the potential for this system to help patients with BPH and increase the number of men choosing MITs, because it offers long-term relief from symptoms without the side effects of medications."

More articles on supply chain:
Stryker CEO sees orthopedics moving to ASCs — But how fast?
4 things to know about Salix Pharmaceuticals
Exact Sciences surpasses investor predictions — Cologuard revenue hits $90.3M

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers